Puma Biotechnology Inc (NASDAQ:PBYI)

3.75
Delayed Data
As of 3:52pm ET
 -0.15 / -3.85%
Today’s Change
2.13
Today|||52-Week Range
5.16
-11.35%
Year-to-Date
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
11:27am / Zacks.com - Paid Partner Content
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
Nov 29 / Zacks.com - Paid Partner Content
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
8:57am / Zacks.com - Paid Partner Content
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
Nov 29 / Zacks.com - Paid Partner Content
Here Is Why Bargain Hunters Would Love Fast-paced Mover Puma Biotech (PBYI)
8:50am / Zacks.com - Paid Partner Content
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
Nov 28 / Zacks.com - Paid Partner Content
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
7:42am / Zacks.com - Paid Partner Content
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
Nov 28 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
Nov 30 / Zacks.com - Paid Partner Content
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
Nov 28 / Zacks.com - Paid Partner Content
FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug
Nov 30 / Zacks.com - Paid Partner Content
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study
Nov 27 / Zacks.com - Paid Partner Content
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Nov 30 / Zacks.com - Paid Partner Content
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
Nov 23 / Zacks.com - Paid Partner Content
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
Nov 30 / Zacks.com - Paid Partner Content
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
Nov 22 / Zacks.com - Paid Partner Content
4 Top-Performing Liquid Stock Picks for Robust Returns
Nov 30 / Zacks.com - Paid Partner Content
Here's Why You May Invest in Puma Biotechnology (PBYI) Stock
Nov 20 / Zacks.com - Paid Partner Content
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
Nov 30 / Zacks.com - Paid Partner Content
PBYI vs. TECH: Which Stock Is the Better Value Option?
Nov 20 / Zacks.com - Paid Partner Content
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
Nov 29 / Zacks.com - Paid Partner Content